N013. Progressive reduction of infusion time of Infliximab. Experience in day-hospital
L. Oltra1, N. Cano1, E. Martín2, E. Hinojosa1, J. Hinojosa1, 1Manises Hospital, Inflammatory Bowel Disease Unit – Day Hospital, Manises, Spain, 2University General Hospital, Valencia, Spain
Recent changes in infusion guidelines of Infliximab on September 2011 and clinical experience in security profile from daily practice, suggest the need to know if the shortening of infusion time shows a comparable safety profile. We show our experience in Infliximab infusion time reduction from 2 hours and 30 minutes to 1 hour, attending technical labelling modification, by determining the profile of adverse events occurred.
Observational descriptive retrospective study with 50 consecutive patients enrolled from Chronic Inflammatory Bowel Disease Unit of our institution between January to November 2012, among which 42 have already received Infliximab infusion in 1 hour as they met the following criteria:
- To have undergone three former induction dosages in 2 hours and 30 minutes and not having developed any problem during or after infusion.
- First maintenance dosage in 1 hour and 30 minutes with no adverse events.
- No adverse events registered after second maintenance dosage.
During study period, no adverse reaction was registered in spite of progressive infusion time reduction to 1 hour.
In our experience, Infliximab maintenance infusion in 1 hour for chronic inflammatory bowel disease has shown a suitable profile of security.